Head to Head Comparison: biote (BTMD) vs. Its Peers

biote (NASDAQ:BTMDGet Rating) is one of 59 publicly-traded companies in the “Medicinals & botanicals” industry, but how does it weigh in compared to its rivals? We will compare biote to related businesses based on the strength of its earnings, analyst recommendations, institutional ownership, risk, profitability, valuation and dividends.

Institutional & Insider Ownership

3.8% of biote shares are owned by institutional investors. Comparatively, 12.3% of shares of all “Medicinals & botanicals” companies are owned by institutional investors. 20.0% of biote shares are owned by insiders. Comparatively, 23.9% of shares of all “Medicinals & botanicals” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.


This table compares biote and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
biote 56.20% -49.58% 29.53%
biote Competitors -8.51% -81.72% 22.98%

Earnings & Valuation

This table compares biote and its rivals top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
biote $164.96 million -$970,000.00 97.18
biote Competitors $283.01 million -$110.28 million -1.53

biote’s rivals have higher revenue, but lower earnings than biote. biote is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for biote and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
biote 0 0 5 0 3.00
biote Competitors 213 565 814 45 2.42

biote currently has a consensus price target of $10.40, indicating a potential upside of 78.39%. As a group, “Medicinals & botanicals” companies have a potential upside of 111.76%. Given biote’s rivals higher probable upside, analysts plainly believe biote has less favorable growth aspects than its rivals.

Risk and Volatility

biote has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500. Comparatively, biote’s rivals have a beta of 1.16, indicating that their average share price is 16% more volatile than the S&P 500.


biote beats its rivals on 7 of the 13 factors compared.

About biote

(Get Rating)

biote Corp. operates in medical practice-building business within the hormone optimization space. The company offers a platform for Biote-certified practitioners to optimize imbalances in their patient's hormone, vitamin, and mineral levels, as well as prescribe bioidentical hormone therapies and recommend dietary supplements. It also sells Biote-branded dietary supplements; and sterile pellet insertion kits for men and women. The company was founded in 2011 and is headquartered in Irvine, Texas.

Receive News & Ratings for biote Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for biote and related companies with MarketBeat.com's FREE daily email newsletter.